ADMA concentration changes across the menstrual cycle and during oral contraceptive use: the Cardiovascular Risk in Young Finns Study.
暂无分享,去创建一个
T. Laitinen | T. Lyyra-Laitinen | J. Viikari | O. Raitakari | M. Kähönen | R. Laaksonen | M. Juonala | G. Alfthan | K. Punnonen | S. Heinonen | H. Saarelainen | Nonna Heiskanen | P. Valtonen
[1] M. Doğanay,et al. Effect of non-oral estrogen on risk markers for metabolic syndrome in early surgically menopausal women , 2010, Climacteric : the journal of the International Menopause Society.
[2] E. Giltay,et al. Differential effects of cross-sex hormonal treatment on plasma asymmetric dimethylarginine (ADMA) in healthy male-to-female and female-to-male transsexuals. , 2009, Atherosclerosis.
[3] T. Lehtimäki,et al. Use of combined oral contraceptives alters metabolic determinants and genetic regulation of C‐reactive protein. The Cardiovascular Risk in Young Finns Study , 2009, Scandinavian journal of clinical and laboratory investigation.
[4] Risto Telama,et al. Cohort profile: the cardiovascular risk in Young Finns Study. , 2008, International journal of epidemiology.
[5] T. Laitinen,et al. Serum L-homoarginine concentration is elevated during normal pregnancy and is related to flow-mediated vasodilatation. , 2008, Circulation journal : official journal of the Japanese Circulation Society.
[6] T. Ozgurtas,et al. Metformin and oral contraceptive treatments reduced circulating asymmetric dimethylarginine (ADMA) levels in patients with polycystic ovary syndrome (PCOS). , 2008, Atherosclerosis.
[7] E. Brindle,et al. C-reactive protein across the menstrual cycle. , 2008, American journal of physical anthropology.
[8] R. Huupponen,et al. Adulthood : The Cardiovascular Risk in Young Finns Study Risk Factors Identified in Childhood and Decreased Carotid Artery Elasticity in , 2005 .
[9] P. Kenemans,et al. Effects of intranasal versus oral hormone therapy on asymmetric dimethylarginine in healthy postmenopausal women: a randomized study. , 2007, Atherosclerosis.
[10] T. Laitinen,et al. Brachial Artery Flow-Mediated Dilation and Asymmetrical Dimethylarginine in the Cardiovascular Risk in Young Finns Study , 2007, Circulation.
[11] T. Teerlink,et al. HPLC analysis of ADMA and other methylated L-arginine analogs in biological fluids. , 2007, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
[12] D. Talwar,et al. Biological variation of asymmetric dimethylarginine and related arginine metabolites and analytical performance goals for their measurement in human plasma , 2007, European journal of clinical investigation.
[13] G. Reaven,et al. ADMA is independently related to flow‐mediated vasodilation in subjects at low cardiovascular risk , 2007, European journal of clinical investigation.
[14] N. Bersinger,et al. Serum leptin and C-reactive protein levels in the physiological spontaneous menstrual cycle in reproductive age women. , 2006, European journal of endocrinology.
[15] J. Bełtowski,et al. Asymmetric dimethylarginine (ADMA) as a target for pharmacotherapy. , 2006, Pharmacological reports : PR.
[16] T. Yurdun,et al. Plasma markers of NO synthase activity in women after ovarian hyperstimulation: influence of estradiol on ADMA , 2006, Vascular medicine.
[17] P. Kenemans,et al. Oral, more than transdermal, oestrogen therapy lowers asymmetric dimethylarginine in healthy postmenopausal women: a randomized, placebo‐controlled study , 2006, Journal of internal medicine.
[18] J. Viikari,et al. Distribution and determinants of serum high‐sensitive C‐reactive protein in a population of young adults. The Cardiovascular Risk in Young Finns Study , 2005, Journal of internal medicine.
[19] E. Schwedhelm,et al. Determination of a reference value for NG, NG‐dimethyl‐L‐arginine in 500 subjects , 2005, European journal of clinical investigation.
[20] J. Viikari,et al. The 21‐year follow‐up of the Cardiovascular Risk in Young Finns Study: risk factor levels, secular trends and east–west difference , 2004, Journal of internal medicine.
[21] J. Cooke. NO and angiogenesis. , 2003, Atherosclerosis. Supplements.
[22] S. Nussey,et al. Estrogen Stimulates Dimethylarginine Dimethylaminohydrolase Activity and the Metabolism of Asymmetric Dimethylarginine , 2003, Circulation.
[23] C. Stehouwer,et al. Effect of hormone replacement therapy on plasma levels of the cardiovascular risk factor asymmetric dimethylarginine: a randomized, placebo-controlled 12-week study in healthy early postmenopausal women. , 2003, The Journal of clinical endocrinology and metabolism.
[24] C. Stehouwer,et al. Oestrogen replacement therapy lowers plasma levels of asymmetrical dimethylarginine in healthy postmenopausal women. , 2003, Clinical science.
[25] A. Hingorani,et al. Endothelial dysfunction and raised plasma concentrations of asymmetric dimethylarginine in pregnant women who subsequently develop pre-eclampsia , 2003, The Lancet.
[26] E. Terán,et al. Physiological changes in platelet aggregation and nitric oxide levels during menstrual cycle in healthy women. , 2002, Nitric oxide : biology and chemistry.
[27] J. Jespersen,et al. Hormone replacement therapy: estrogen and progestin effects on plasma C-reactive protein concentrations. , 2002, American journal of obstetrics and gynecology.
[28] R. Nijveldt,et al. Determination of arginine, asymmetric dimethylarginine, and symmetric dimethylarginine in human plasma and other biological samples by high-performance liquid chromatography. , 2002, Analytical biochemistry.
[29] M. Giusti,et al. Circulating nitric oxide changes throughout the menstrual cycle in healthy women and women affected by pathological hyperprolactinemia on dopamine agonist therapy , 2002, Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology.
[30] P. Vallance. Importance of asymmetrical dimethylarginine in cardiovascular risk , 2001, The Lancet.
[31] T. Lehtimäki,et al. Risk of acute coronary events and serum concentration of asymmetrical dimethylarginine , 2001, The Lancet.
[32] C. Zoccali,et al. Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study , 2001, The Lancet.
[33] M. Denton,et al. Dimethylarginines in chronic renal failure , 2001, Journal of clinical pathology.
[34] R. Karas,et al. The protective effects of estrogen on the cardiovascular system. , 2002, The New England journal of medicine.
[35] S. Nussey,et al. Plasma concentrations of asymmetric dimethylarginine, a natural inhibitor of nitric oxide synthase, in normal pregnancy and preeclampsia. , 1998, American journal of obstetrics and gynecology.
[36] M. H. Gault,et al. Prediction of creatinine clearance from serum creatinine. , 1975, Nephron.